Zhejiang Shengda Bio-Pharm Co., Ltd. (603079.SS)
CNY 16.39
(1.42%)
CNY 16.39
(1.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 449.19 Million CNY | 44.08% |
| 2022 | 311.76 Million CNY | -27.13% |
| 2021 | 427.84 Million CNY | 13.85% |
| 2020 | 375.8 Million CNY | -39.47% |
| 2019 | 620.88 Million CNY | 46.33% |
| 2018 | 424.29 Million CNY | 95.28% |
| 2017 | 217.27 Million CNY | -27.9% |
| 2016 | 301.35 Million CNY | 62.85% |
| 2015 | 185.04 Million CNY | -17.17% |
| 2014 | 223.39 Million CNY | -0.27% |
| 2013 | 224 Million CNY | -30.31% |
| 2012 | 321.42 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 493.01 Million CNY | 9.75% |
| 2024 Q3 | 465.53 Million CNY | 10.62% |
| 2024 Q2 | 420.83 Million CNY | -14.64% |
| 2023 Q2 | 332.42 Million CNY | 23.91% |
| 2023 FY | 449.19 Million CNY | 44.08% |
| 2023 Q4 | 449.19 Million CNY | 19.41% |
| 2023 Q1 | 268.28 Million CNY | -13.94% |
| 2023 Q3 | 376.17 Million CNY | 13.16% |
| 2022 Q1 | 442.29 Million CNY | 3.38% |
| 2022 FY | 311.76 Million CNY | -27.13% |
| 2022 Q4 | 311.76 Million CNY | -0.34% |
| 2022 Q3 | 312.81 Million CNY | -21.19% |
| 2022 Q2 | 396.91 Million CNY | -10.26% |
| 2021 Q2 | 480.3 Million CNY | 0.46% |
| 2021 Q1 | 478.09 Million CNY | 27.22% |
| 2021 Q4 | 427.84 Million CNY | 4.26% |
| 2021 Q3 | 410.37 Million CNY | -14.56% |
| 2021 FY | 427.84 Million CNY | 13.85% |
| 2020 Q3 | 339.81 Million CNY | -1.89% |
| 2020 Q1 | 384.59 Million CNY | -38.06% |
| 2020 FY | 375.8 Million CNY | -39.47% |
| 2020 Q2 | 346.35 Million CNY | -9.94% |
| 2020 Q4 | 375.8 Million CNY | 10.59% |
| 2019 FY | 620.88 Million CNY | 46.33% |
| 2019 Q4 | 620.88 Million CNY | 3.98% |
| 2019 Q3 | 597.12 Million CNY | 21.79% |
| 2019 Q1 | 492.83 Million CNY | 16.15% |
| 2019 Q2 | 490.3 Million CNY | -0.51% |
| 2018 Q1 | 214.35 Million CNY | -1.34% |
| 2018 Q2 | 216.53 Million CNY | 1.02% |
| 2018 Q3 | 258.54 Million CNY | 19.4% |
| 2018 Q4 | 424.29 Million CNY | 64.11% |
| 2018 FY | 424.29 Million CNY | 95.28% |
| 2017 Q3 | 235.99 Million CNY | -2.09% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q2 | 241.02 Million CNY | 0.0% |
| 2017 Q4 | 217.27 Million CNY | -7.93% |
| 2017 FY | 217.27 Million CNY | -27.9% |
| 2016 FY | 301.35 Million CNY | 62.85% |
| 2016 Q4 | 301.35 Million CNY | 0.0% |
| 2015 Q4 | 185.04 Million CNY | 0.0% |
| 2015 Q1 | 240.61 Million CNY | 0.0% |
| 2015 FY | 185.04 Million CNY | -17.17% |
| 2015 Q2 | 240.61 Million CNY | 0.0% |
| 2014 FY | 223.39 Million CNY | -0.27% |
| 2013 FY | 224 Million CNY | -30.31% |
| 2012 FY | 321.42 Million CNY | 0.0% |